#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Multiple sclerosis, a treatable disease."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/4aa36980578c7d2cff07371abf768f15db89cd11/export/conso-names.belns"
 DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
 DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/0816cb6686751420365441adc6a28ced2d272f14/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
 DEFINE NAMESPACE NCIT           AS PATTERN "^C\d+$"
###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
# DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
# DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "27956442"}

SET Evidence = "MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems."
path(MESH:"Multiple Sclerosis") isA path(MESH:"Central Nervous System Diseases")
path(MESH:"Multiple Sclerosis") -- path(MESH:Inflammation)
path(MESH:"Multiple Sclerosis") -- a(MESH:"Motor Neurons")
path(MESH:"Multiple Sclerosis") -- path(MESH:Sensation)
path(MESH:"Multiple Sclerosis") -- path(MESH:"Autonomic Nervous System")

SET Evidence = "Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation
or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock
like sensation down the spine or limbs on neck flexion) are characteristic of MS.[3–5]"
#NCIT:C28314 - Lhermitte's phenomenon
path(MESH:"Multiple Sclerosis") -- path(MESH:"Optic Neuritis")
path(MESH:"Multiple Sclerosis") -- path(MESH:"Body Temperature Changes")
path(MESH:"Multiple Sclerosis") -- path(NCIT:C28314)

SET Evidence = "CIS encompasses an acute clinical attack affecting one or more CNS sites and can convert to relapsing remitting MS (RRMS)."
#Clinically isolated syndrome (CIS) - Demyelinating Diseases
path(MESH:"Demyelinating Diseases") neg path(MESH:"Central Nervous System")
path(MESH:"Demyelinating Diseases") -> path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

######how to code tloc() across BBB
SET Evidence = "These early stages of MS with underlying demyelination are thought to have an inflammatory pathological substrate with migration of autoreactive lymphocytes across the blood-brain barrier."
#these - CIS and RRMS
path(MESH:"Demyelinating Diseases") -- path(MESH:Inflammation)
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") -- path(MESH:Inflammation)
SET MeSHAnatomy = "Lymphocytes"
path(MESH:"Demyelinating Diseases") -> tloc(a(MESH:Lymphocytes), fromLoc(GO:cytoplasm), toLoc(MESH:"Blood-Brain Barrier"))
path(MESH:"Multiple Sclerosis, Relapsing-Remitting") -> bp(GO:"transport across blood-brain barrier")
UNSET MeSHAnatomy

####Change according to above sentence change.
SET Evidence = "This triggers a cascade of inflammation with T- and B-cell clonal expansion, and microglia activation and oxidative damage, mitochondrial injury and energy failure, leading to the
development of the characteristic plaque. [15,16]"
SET MeSHAnatomy = {"T-Lymphocytes", "B-Lymphocytes"}
bp(GO:"transport across blood-brain barrier") => path(NCIT:C20613)
path(NCIT:C20613) => path(MESH:Inflammation)
UNSET MeSHAnatomy
bp(GO:"transport across blood-brain barrier") => bp(GO:"microglial cell activation")
bp(GO:"microglial cell activation") => path(MESH:Inflammation)
bp(GO:"transport across blood-brain barrier") => path(MESH:"Oxidative Stress")
path(MESH:"Oxidative Stress") => path(MESH:Inflammation)
bp(GO:"transport across blood-brain barrier") => path(MESH:"Mitochondrial Diseases")
path(MESH:"Mitochondrial Diseases") => path(MESH:Inflammation)
bp(GO:"transport across blood-brain barrier") neg path(MESH:"Energy Metabolism")
path(MESH:"Energy Metabolism") neg path(MESH:Inflammation)
path(MESH:Inflammation) => path(NCIT:C95603)

SET Evidence = "There is further axonal injury and atrophy in both white and grey matter, with a likely underlying
neurodegenerative pathogenesis, but less inflammation. [16,18]"
#in case of secondary progressive MS (SPMS) - Multiple Sclerosis, Chronic Progressive
SET MeSHAnatomy = {"White Matter", "Gray Matter"}
path(MESH:"Multiple Sclerosis, Chronic Progressive") => path(MESH:"Diffuse Axonal Injury")
path(MESH:"Multiple Sclerosis, Chronic Progressive") => path(MESH:Atrophy)
path(MESH:"Multiple Sclerosis, Chronic Progressive") -> path(MESH:Inflammation)
path(MESH:"Diffuse Axonal Injury") -> path(MESH:"Neurodegenerative Diseases")
path(MESH:Atrophy) -> path(MESH:"Neurodegenerative Diseases")
UNSET MeSHAnatomy

SET Evidence = "10–15% of patients have progressive disability from the outset, usually due to spinal cord disease. This is defined as primary progressive MS (PPMS). 1,3,20"
path(MESH:"Multiple Sclerosis, Chronic Progressive") => path(MESH:"Spinal Cord Diseases")
path(MESH:"Spinal Cord Diseases") -> path(EFO:"movement disorder")

SET Evidence = "Due to spinal cord dysfunction, patients often have a progressive spastic paraparesis."
path(MESH:"Spinal Cord Diseases") => path(MESH:"Paraparesis, Spastic")

SET Evidence = "The pathological basis appears to be more diffuse brain axonal loss and further microglial activation with atrophy."
path(MESH:"Paraparesis, Spastic") => path(MESH:"Diffuse Axonal Injury")
path(MESH:Atrophy) => bp(GO:"microglial cell activation")

SET Evidence = "There is anterograde and retrograde neurodegeneration with oxidative damage and energy failure."
path(MESH:"Oxidative Stress") -> path(MESH:"Amnesia, Anterograde")
path(MESH:"Oxidative Stress") -> path(MESH:"Amnesia, Retrograde")
path(MESH:"Energy Metabolism") -| path(MESH:"Amnesia, Anterograde")
path(MESH:"Energy Metabolism") -| path(MESH:"Amnesia, Retrograde")

SET Evidence = "Meta-analyses suggest that the strongest evidence of association is related to Epstein-Barr virus biomarker positivity, infectious mononucleosis and smoking. [21]"
#biomarker for MS
path(MESH:"Epstein-Barr Virus Infections") pos path(MESH:"Multiple Sclerosis")
path(MESH:"Infectious Mononucleosis") pos path(MESH:"Multiple Sclerosis")
path(MESH:Smoking) pos path(MESH:"Multiple Sclerosis")

SET Evidence = "If the relapse is of moderate functional severity or worse, then high-dose
methylprednisolone therapy should be considered, at a dose of 500–1,000 mg per day for 3–5 days as per local guidelines."
#dose - 500 to 1000mg/day
#3-5 days
a(CHEBI:"6-methylprednisolone") =| path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

SET Evidence = "While not disease-modifying, corticosteroids tend to shorten the duration of the relapse."
a(CHEBI:corticosteroid) -| path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

SET Evidence = "Plasma exchange is occasionally used, as an adjunctive therapy or alone, if the relapse is rapidly progressive or severe. Therapy interventions, such as physiotherapy, should also be used early
to enhance recovery. [4]"
path(MESH:"Plasma Exchange") =| path(MESH:"Multiple Sclerosis, Relapsing-Remitting")
path(MESH:"Physical Therapy Modalities") -| path(MESH:"Multiple Sclerosis, Relapsing-Remitting")

SET Evidence = "The most serious side effect occurred unexpectedly about a decade ago with natalizumab – a humanised monoclonal antibody against the cell adhesion molecule alpha 4-integrin – where
activation of the John Cunningham virus (JCV) resulted in progressive multifocal leukoencephalopathy (PML)."
a(PUBCHEM:135314782) =| p(HGNC:ITGA4)
p(HGNC:ITGA4) isA a(MESH:"Cell Adhesion Molecules")
a(PUBCHEM:135314782) => path(MESH:"JC Virus")
path(MESH:"JC Virus") -> path(MESH:"Leukoencephalopathy, Progressive Multifocal")

SET Evidence = "PML has also been recently observed, much more rarely, with the oral agents fingolimod and dimethylfumarate. [4,11]"
a(PUBCHEM:107970) -> path(MESH:"Leukoencephalopathy, Progressive Multifocal")
a(PUBCHEM:637568) -> path(MESH:"Leukoencephalopathy, Progressive Multifocal")

SET Evidence = "β-interferons and glatiramer acetate are currently the only licensed therapies
for CIS in the UK"
a(PUBCHEM:223370366) -| path(MESH:"Demyelinating Diseases")
a(PUBCHEM:3081884) -| path(MESH:"Demyelinating Diseases")

SET Evidence = "In rapidly progressing SPMS patients, intravenous mitoxantrone can be considered, but this
requires close monitoring for cardiac side effects and acute myelogenous leukaemia."
a(PUBCHEM:4212) =| path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(PUBCHEM:4212) -> path(MESH:"Arrhythmias, Cardiac")
a(PUBCHEM:4212) -> path(MESH:"Leukemia, Myeloid, Acute")

SET Evidence = "There are a large number of phase III trials using agents such azathioprine, ciclosporin, β-interferon, dirucotide (myelin basic protein), immunoglobulins and cladribine, as well as other immunomodulators, in progressive MS that have been reported over the last 25 years. Unfortunately,
the results have essentially been negative. [10]"
a(PUBCHEM:2265) cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(PUBCHEM:5284373) cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(PUBCHEM:223370366) cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(PUBCHEM:44151255) cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(MESH:Immunoglobulins) cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(PUBCHEM:20279) cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(MESH:"Immunologic Factors") cnc path(MESH:"Multiple Sclerosis, Chronic Progressive")

SET Evidence = "However, the counter to this may be the recently announced groundbreaking results from the ORATORIO trial (NCT01194570, ClinicalTrials.gov) of ocrelizumab – an anti-CD20 depleting molecule – in PPMS and the EXPAND trial (NCT01665144, ClinicalTrials.gov) of siponimod – a selective sphingosine-1-phosphate receptor modulator – in SPMS that delayed the confirmed progression of MS by about 20–25% over 2–3 years [34,35]"
a(PUBCHEM:47206937) =| p(HGNC:MS4A1)
a(PUBCHEM:47206937) -| path(MESH:"Multiple Sclerosis, Chronic Progressive")
a(PUBCHEM:44599207) reg p(HGNCGENEFAMILY:"Sphingosine 1-phosphate receptors")
a(PUBCHEM:44599207) -| path(MESH:"Multiple Sclerosis, Chronic Progressive")

SET Evidence = "Table 1. UK-licensed disease-modifying treatments (DMTs) for relapsing remitting MS [11,27–30]"
#less than 1:100
#47206399 - Avonex
#Alopecia - hair loss/thinning
a(PUBCHEM:47206399) -> path(MESH:Headache)
a(PUBCHEM:47206399) -> path(MESH:Lymphopenia)
a(PUBCHEM:47206399) -> path(MESH:"Sleep Initiation and Maintenance Disorders")
a(PUBCHEM:47206399) -> path(MESH:Diarrhea)
a(PUBCHEM:47206399) -> path(MESH:Nausea)
a(PUBCHEM:47206399) -> path(MESH:Vomiting)
a(PUBCHEM:47206399) -> path(MESH:Depression)
a(PUBCHEM:47206399) -> path(MESH:Alopecia)
a(PUBCHEM:47206399) -> path(MESH:"Thyroid Diseases")
#172232576 - Plegridy
a(PUBCHEM:172232576) -> path(MESH:Headache)
a(PUBCHEM:172232576) -> path(MESH:Lymphopenia)
a(PUBCHEM:172232576) -> path(MESH:"Sleep Initiation and Maintenance Disorders")
a(PUBCHEM:172232576) -> path(MESH:Diarrhea)
a(PUBCHEM:172232576) -> path(MESH:Nausea)
a(PUBCHEM:172232576) -> path(MESH:Vomiting)
a(PUBCHEM:172232576) -> path(MESH:Depression)
a(PUBCHEM:172232576) -> path(MESH:Alopecia)
a(PUBCHEM:172232576) -> path(MESH:"Liver Diseases")
a(PUBCHEM:172232576) -> path(MESH:"Thyroid Diseases")
#50070200 - Rebif
a(PUBCHEM:50070200) -> path(MESH:Headache)
a(PUBCHEM:50070200) -> path(MESH:Lymphopenia)
a(PUBCHEM:50070200) -> path(MESH:"Sleep Initiation and Maintenance Disorders")
a(PUBCHEM:50070200) -> path(MESH:Diarrhea)
a(PUBCHEM:50070200) -> path(MESH:Nausea)
a(PUBCHEM:50070200) -> path(MESH:Vomiting)
a(PUBCHEM:50070200) -> path(MESH:Depression)
a(PUBCHEM:50070200) -> path(MESH:Alopecia)
a(PUBCHEM:50070200) -> path(MESH:"Liver Diseases")
a(PUBCHEM:50070200) -> path(MESH:"Thyroid Diseases")
#3081884 - Copaxone
a(PUBCHEM:50070200) -> path(HP:Lipoatrophy)
a(PUBCHEM:50070200) -> path(MESH:Headache)
a(PUBCHEM:50070200) -> path(MESH:Depression)
a(PUBCHEM:50070200) -> path(MESH:Anxiety)
a(PUBCHEM:50070200) -> path(MESH:Nausea)
a(PUBCHEM:50070200) -> path(MESH:Flushing)
a(PUBCHEM:50070200) -> path(HP:Palpitations)
a(PUBCHEM:50070200) -> path(MESH:Dyspnea)
a(PUBCHEM:50070200) -> path(MESH:Chest Pain)
#54684141 - Aubagio
a(PUBCHEM:54684141) -> path(MESH:"Liver Diseases")
a(PUBCHEM:54684141) -> path(MESH:Diarrhea)
a(PUBCHEM:54684141) -> path(MESH:Alopecia)
#637568 - Tecfidera
#Exanthema - Rash
a(PUBCHEM:637568) -> path(MESH:Flushing)
a(PUBCHEM:637568) -> path(MESH:"Gastrointestinal Diseases")
a(PUBCHEM:637568) -> path(MESH:Lymphopenia)
a(PUBCHEM:637568) -> path(MESH:Exanthema)
a(PUBCHEM:637568) -> path(MESH:Ketosis)
a(PUBCHEM:637568) -> path(MESH:Proteinuria)
a(PUBCHEM:637568) -> path(MESH:"Liver Diseases")
#107970 - Gilenya
a(PUBCHEM:107970) -> path(MESH:Cough)
a(PUBCHEM:107970) -> path(MESH:Headache)
a(PUBCHEM:107970) -> path(MESH:"Back Pain")
a(PUBCHEM:107970) -> path(MESH:Diarrhea)
a(PUBCHEM:107970) -> path(MESH:Infection)
a(PUBCHEM:107970) -> path(MESH:"Liver Diseases")
a(PUBCHEM:107970) -> path(MESH:Lymphopenia)
#more than 1:100
a(PUBCHEM:107970) -> path(MESH:"Macular Edema")
#135314782 - Tysabri
a(PUBCHEM:135314782) -> path(MESH:Headache)
a(PUBCHEM:135314782) -> path(MESH:Dizziness)
a(PUBCHEM:135314782) -> path(MESH:Exanthema)
a(PUBCHEM:135314782) -> path(MESH:Infection)
#^C\d+$ - NCIT
#135330159  - Lemtrada
#endocrinopathy - POEMS Syndrome
a(PUBCHEM:135330159) -> path(NCIT:C78251)
a(PUBCHEM:135330159) -> path(MESH:Headache)
a(PUBCHEM:135330159) -> path(MESH:Exanthema)
a(PUBCHEM:135330159) -> path(MESH:Fever)
a(PUBCHEM:135330159) -> path(MESH:Nausea)
a(PUBCHEM:135330159) -> path(MESH:Diarrhea)
a(PUBCHEM:135330159) -> path(MESH:Hypotension)
a(PUBCHEM:135330159) -> path(MESH:"Herpes Simplex")
a(PUBCHEM:135330159) -> path(MESH:"POEMS Syndrome")
